ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO150

Factors Associated with AKI in Mexican Patients with Acute Coronary Syndromes

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Ramirez-Flores, Diana, Nephrology and Trasplant Unit HE, IMSS, Zapopan, Mexico
  • Banda Lopez, Adriana, Nephrology and Trasplant Unit HE, IMSS, Zapopan, Mexico
  • Flores Fonseca, Milagros Melissa, Centro Medico Nacional de Occidente, Guadalajara, Mexico
  • Parra-Michel, Rodolfo, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Maldonado Gomez, Victoria G., Nephrology and Trasplant Unit HE, IMSS, Zapopan, Mexico
  • Gomez-Navarro, Benjamin, IMSS, HECMNO, Zapopan, Jalisco, Mexico

AKI is a leading cause of morbidity and mortality in hospitalized patients with ACS. The aim of this study was to identify potential risk factors and patient characteristics associated in patients with ACS.


We analyze a single center retrospective review of 77 patients with ACS. The sCr at hospital and daily during the coronary unit was available for analyzed patients to diagnose AKI. Demographics, clinical and biochemical profiles, risk factors for AKI and RRT prescription was assessed and reported during diagnosis and discharge. Outcome measures were renal recovery, mortality and causes of death. Statistical analysis was done with SPSS version 26.0. The categorical variables were analyzed using chi-square test or Fisher’s exact probability test, as appropriate. The continuous variables were analyzed using the Student’s t test. A value of p < 0.05 was regarded as statistically significant.


Mean age was 65.45 ± 10.84 years and 70% were male. AKI was diagnosed in 50% of ACS cases. The mortality rate was 31% due to cardiovascular complications. Pre-existing comorbidities and other factors found to have increased association with AKI presence were: CKD (p < 0.0001), diabetes with complications (p=0.031), bacteremia (p=0.028), history of surgery complications (p<0.0001), nephrotoxic use (p=0.004) and biochemical alterations as anemia, hyperbilirubinemia, hyperglycemia, hyperlactatemia, metabolic acidosis, and elevated cardiac biomarkers (p<0.05).


This study shows that AKI is a frequent complication of ACS and its association with predictive factors. Further studies are needed to stablish early strategies aimed to preventing AKI or at reducing its severity might provide significant clinical benefit in patients with ACS.

Comparison of AKI presence in ACS patients
N = 39
N = 38
Age (years)67.41 ± 11.2263.45 ± 10.190.818
Body mass index (kg/m2)28.47 ± 3.9727.98 ± 4.960.066
Procalcitonin (ng/ml)26.36 ± 60.780.58 ± 0.930.001
Lactate dehydrogenase (U/L)5522.47 ± 7329.03742.58 ± 627.69<0.001
Troponin I (mcg/L)1719.92 ± 7038.7015752.55 ± 16133.56<0.001
B type natriuretic peptide (pg/ml)1719.92 ± 7038.703039.23 ± 4928.30<0.001
Serum creatinine (mg/dl)15208.67 ± 9787.680.90 ± 0.31<0.001
Uresis (ml)0.50 ± 0.390.74 ± 0.230.018